Refinement of the symptom screening in pediatrics tool (SSPedi).

BACKGROUND: Objective was to evaluate and refine a new instrument for paediatric cancer symptom screening named the Symptom Screening in Pediatrics Tool (SSPedi). METHODS: Respondents were children 8-18 years of age undergoing active cancer treatment and parents of eligible children. Respondents completed SSPedi once and then responded to semi-structured questions. They rated how easy or difficult SSPedi was to complete. For items containing two concepts, we asked respondents whether concepts should remain together or be separated into two questions. We also asked about each item's importance and whether items were missing. Cognitive probing was conducted in children to evaluate their understanding of items and the response scale. After each group of 10 children and 10 parents, responses were reviewed to determine whether modifications were required. Recruitment ceased with the first group of 10 children in which modifications were not required. RESULTS: Thirty children and 20 parents were required to achieve a final version of SSPedi. Fifteen items remain in the final version; the score ranges from 0 to 60. CONCLUSIONS: Using opinions of children with cancer and parents of paediatric cancer patients, we successfully developed a symptom screening tool that is easy to complete, is understandable and demonstrates content validity.

Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea.

OBJECTIVE: Hyperproinsulinemia in type 2 diabetic subjects has recently been accepted as an independent cardiovascular risk factor. Moreover, it has been confirmed that high proinsulin concentrations stimulate amylin secretion by pancreatic beta-cells and amyloid accumulation within pancreatic islets leading to impairment of pancreatic islets secretory function. The association between sulfonylureas administration and secretory function of pancreatic beta-cells, especially concerning insulin precursor peptides, is not sufficiently elucidated. Preliminary studies by our research group revealed that the fasting proinsulin serum concentration is significantly higher in type 2 diabetic patients treated with sulfonylureas than in a well-matched group treated with insulin only. METHODS: A total of 101 subjects with type 2 diabetes were treated either with sulfonylureas (n = 32), with insulin (n = 40), with sulfonylureas + insulin (n = 17) or with diet alone (n = 12). RESULTS: The basal secretory function in the four groups were comparable (C-peptide fasting serum level > 0.5 ng/l). An effect of fasting glycemia, long-term metabolic control (HbA1c), postprandial hyperglycemia (1,5-anhydro-D-glucitol), insulin resistance (HOMA(IR)score) and diabetes duration on the fasting proinsulin serum level in the subjects treated could be excluded. CONCLUSION: The disproportionately high proinsulin levels are due to sulfonylureas therapy. The effect is independent of fasting glycemia, long-term metabolic control, postprandial hyperglycemia, diabetes duration and peripheral insulin resistance.

Usefulness of two methods of isoelectric focusing for the erythrocyte acid phosphatase phenotypes determination in human bloodstains.

The authors tried to compare the usefulness of the isoelectric focusing of EAP in bloodstains on 0.2 mm polyacrylamide gel with their method of determination of the enzyme on 1 mm polyacrylamide gel. Both methods turned out to be useful but better results were obtained on 0.2 mm gel. Isoelectric focusing on the ultra-thin gel is more sensitive; it gives clear enzyme strips, takes less time (30 min) and demands about half the amount of material.

Lower melanin content in the skin of type 1 diabetic patients and the risk of microangiopathy.

BACKGROUND: Various skin diseases are commonly observed in diabetic patients. Typical biophysical properties of diabetic skin such as lower skin elasticity, decreased water content in stratum corneum, increased itching and sweating disturbances are reported. The aim of the study was to examine the distribution and intensity of skin pigmentation in diabetic patients in correlation with the metabolic control and with presence of microangiopathy. MATERIAL AND METHODS: The study was conducted on 105 patients (42 men and 63 women, median age 31), with type 1 diabetes (DM1). The control group of 53 healthy individuals (22 men and 31 women) was age- and sex-matched. Skin pigmentation was measured at 3 different locations of the body (cheek, dorsal surface of a forearm and dorsal surface of a foot) using Mexameter® MX 18. We calculated melanin index (MI) by the meter from the intensities of absorbed and reflected light at 880 nm. RESULTS: Patients with DM1 had lower MI on the foot (173.2 ± 38.8 vs. 193.4 ± 52.7, p=0.016) as compared to controls. In the univariate analysis cheek MI was negatively related to HbA1c level (ß=-4.53, p=0.01). Forearm MI was negatively associated with daily insulin dose (ß=-0.58, p=0.01), BMI (ß=-3.02, p<0.001), waist circumference (ß=-0.75, p=0.009), serum TG concentration (ß=-18.47, p<0.001) and positively with HDL cholesterol level (ß=15.76, p=0.02). Diabetic patients with hypertension had lower foot MI values (ß=-18.28, p=0.03). Lower MI was associated with the presence of diabetic neuropathy (ß=-18.67, p=0.04) and retinopathy (ß=-17.47, p=0.03). CONCLUSIONS: In conclusion, there seems to be loss of melanocytes in type 1 diabetes. The melanin content is related to glycemic control of diabetes and obesity. The lower melanin content the higher possibility of microangiopathy. This is a first report in the literature devoted to distribution of melanin in the skin of type 1 diabetic patients.